On July 28, Charles River Laboratories rose 7.74% in regular trading, trading at $235.42/share, with turnover of $79.61 million. The stock surged amid a broad CRO sector rally coupled with multiple investment bank price target upgrades ahead of the upcoming Q2 earnings release.

Deutsche Bank published a Q2 CRO industry outlook report indicating that macro indicators are trending positively across the board, with AI-related fears subsiding and cyclical recovery forming a dual catalyst. Q2 marked the third-highest quarter for biotech equity financing on record. Meanwhile, several investment banks recently raised their price targets on Charles River: Baird lifted its target from $213 to $255, Morgan Stanley from $220 to $260, and Evercore ISI from $220 to $260, all maintaining overweight or outperform ratings.

The company is scheduled to report Q2 earnings on August 5 before market open, with consensus EPS estimates at $2.72. Within the Life Sciences Tools & Services sector, IQVIA rose 12.54%, Repligen gained 13.22%, Thermo Fisher Scientific advanced 2.84%, and Danaher added 2.11%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)